Anti-integrin therapy for inflammatory bowel disease

doi:10.3748/wjg.v24.i17.1868

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 24, Issue 17

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (15324)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

1330

HTML

11407

Figures (1-2)

462

Tables (1-2)

217

Sum=13416

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

960

Download

948

Sum=1908

May 7, 2018 (publication date) through Jun 29, 2024

Times Cited of This Article

Times Cited (81)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastroenterol. May 7, 2018; 24(17): 1868-1880
Published online May 7, 2018. doi: 10.3748/wjg.v24.i17.1868

Table 1 Anti-integrin therapies for inflammatory bowel disease

Drug	Formula	Target	Route	Clinical studies	Summary
Natalizumab	Humanized IgG₄ mAb	α4-integrin	i.v.	ENCORE	Induction and maintenance in CD
AJM300	Small molecule	α4-integrin	Oral	Phase IIa	Induction in UC
Vedolizumab	Humanized IgG₁ mAb	α4β7-integrin	i.v.	GEMINI 1	Induction and maintenance in UC
				GEMINI 2	Induction and maintenance in CD
				GEMINI 3	Induction in CD
Abrilumab (AMG 181/MEDI 7183)	Fully human IgG₂ mAb	α4β7-integrin	s.c.	Phase IIb	Induction in UC
Abrilumab (AMG 181/MEDI 7183)	Fully human IgG₂ mAb	α4β7-integrin	s.c.	Phase IIb	Induction in CD
Etrolizumab	Humanized IgG₁ mAb	β7-integrin	i.v./s.c.	EUCALYPTUS	Induction in UC
				BERGAMOT	Induction in CD
				HICKORY	Induction in CD
PF-00547659 (SHP647)	Fully human IgG_2κ mAb	MAdCAM-1	i.v./s.c.	TURANDOT	Induction in UC
PF-00547659 (SHP647)	Fully human IgG_2κ mAb	MAdCAM-1	i.v./s.c.	OPERA	Induction in CD

IgG: Immunoglobulin; mAb: Monoclonal antibody; i.v.: Intravenous; CD: Crohn’s disease; UC: Ulcerative colitis; s.c.: Subcutaneous; MAdCAM: Mucosal addressin cell adhesion molecule.

Citation: Park SC, Jeen YT. Anti-integrin therapy for inflammatory bowel disease. World J Gastroenterol 2018; 24(17): 1868-1880
URL: https://www.wjgnet.com/1007-9327/full/v24/i17/1868.htm
DOI: https://dx.doi.org/10.3748/wjg.v24.i17.1868